Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients

被引:14
|
作者
Martinelli, Domenico [1 ,2 ]
Tafuri, Silvio [2 ,3 ]
Caputi, Giovanni [2 ,3 ]
Fortunato, Francesca [2 ,3 ]
Reggio, Paolo [4 ]
Germinario, Cinzia [2 ,3 ]
Prato, Rosa [1 ,2 ]
机构
[1] Univ Foggia, Sez Igine, Dipartimento Sci Med & Lavoro, I-71000 Foggia, Italy
[2] Epidemiol Observ Puglia Reg, Bari, Italy
[3] Univ Bari, Sect Hyg, Dept Biomed Sci & Human Oncol, Bari, Italy
[4] Sanofi Pasteur MSD SpA, Rome, Italy
关键词
Pneumococcal 23-valent polysaccharide vaccine; invasive pneumococcal disease; vaccination coverage rate; COST-EFFECTIVENESS; OLDER-ADULTS; REVACCINATION; PNEUMONIA; DISEASE;
D O I
10.1016/j.ajic.2009.09.019
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Streptococcus pneumoniae, lancet-shaped, gram-positive, facultative anaerobic organisms, are common inhabitants of the respiratory tract and may be isolated from the nasopharynx of 5% to 70% of healthy adults. Objective: The aims of the study were to estimate the vaccination coverage for pneumococcal 23-valent polysaccharide vaccine and to assess the impact its introduction in the Italian region of Puglia, where a program to provide this vaccination has been operative since 2000. Methods: Estimation of the coverage for pneumococcal 23-valent polysaccharide vaccine was implemented by a 2-step study consisting of data collection from local health unit vaccination registers between 2000 and 2008 in Puglia and of a cluster sampling study among general practitioners to validate routine data collected during the first step. Moreover, hospitalization for invasive pneumococcal diseases was studied. Results: From 2000 to 2004, among individuals >= 65 years, the overall coverage rate estimated by routine data amounted to 26.3%; between 2005 and 2007, annual coverage rates did not exceed 8%/year. Between 2002 and 2007, the overall coverage rate estimated by interviewing general practitioners was 46.6% (95% confidence interval: 39.9-53.4). The coverage rate in chronic patients by routine data was approximately 23%, whereas the rate provided by general practitioners was 17.6% (95% confidence interval: 12.5-22.8). From 2001 to 2007, hospitalization data did not show a reduction in invasive pneumococcal disease trends among the elderly population in Puglia. Conclusion: The results of this study demonstrate the need for improving vaccine coverage and implementing new immunization strategies and practices.
引用
收藏
页码:E8 / E15
页数:8
相关论文
共 50 条
  • [1] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
    Shiramoto, Masanari
    Hanada, Ryuzo
    Juergens, Christine
    Shoji, Yasuko
    Yoshida, Mizuki
    Ballan, Barry
    Cooper, David
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
  • [2] A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older
    Kawakami, Kenji
    Nakamura, Atsushi
    Wakana, Akira
    Folaranmi, Temitope A.
    Iino, Tomoharu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (07) : 1521 - 1528
  • [3] Immunogenicity of A 23-Valent Pneumococcal Polysaccharide Vaccine Among Mexican Children
    Elva Espinosa-Padilla, Sara
    Murata, Chiharu
    Estrada-Parra, Sergio
    Santos-Argumedo, Leopoldo
    Mascarenas, Cesar
    Franco-Paredes, Carlos
    Javier Espinosa-Rosales, Francisco
    ARCHIVES OF MEDICAL RESEARCH, 2012, 43 (05) : 402 - 405
  • [4] No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
    Hsieh, Meng-Jer
    Yu, Chun-Chen
    Hu, Han-Chung
    Thai, Ying-Huang
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [5] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Malene, B. Mikkelsen
    Oyvind, Husby
    Tor, Molden
    David, N. Mwaura
    Jens, Olsen
    Nanna, V. Kristensen
    Jeffrey, Vietri
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [6] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [7] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [8] Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
    Ohshima, Nobuharu
    Akeda, Yukihiro
    Nagai, Hideaki
    Oishi, Kazunori
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (09) : 2285 - 2291
  • [9] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Jackson, Lisa A.
    Gurtman, Alejandra
    Rice, Kathryn
    Pauksens, Karlis
    Greenberg, Richard N.
    Jones, Thomas R.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3585 - 3593
  • [10] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878